Characteristics and outcome of systemic treatment for metastatic or unresectable thymic carcinoma: A single institution experience.
Thorac Cancer
; 15(4): 339-346, 2024 Feb.
Article
in En
| MEDLINE
| ID: mdl-38149471
ABSTRACT
BACKGROUND:
Thymic carcinoma is a rare disease with an incidence of around 0.5 cases per million with a poor prognosis. The aim of this study was to assess patient outcomes with advanced thymic carcinoma receiving first-line chemotherapy.METHODS:
In our retrospective cohort study, we included patients who underwent treatment for metastatic thymic carcinoma between January 2013 to December 2019 in our hospital. Overall survival, progression-free survival (PFS), objective response rates (ORR) and chemotherapy regimens were assessed and analyzed.RESULTS:
A total of 27 patients were retrospectively analyzed. All patients received a platinum (cisplatin or carboplatin) based regimen as first-line chemotherapy (29.6% received ADOC, 11.1% received PE, 40.7% received CP, 14.8% received CAP). The median PFS on first-line chemotherapy was 199 days. The response rate was 40.7%. Median overall survival (OS) was 585 days. Positive CD5 staining was associated with better PFS.CONCLUSION:
We highlight the critical role of platinum-based chemotherapy agents as a primary treatment modality in advanced thymic carcinoma, underscoring the efficacy of platinum as a first-line option for recurrent disease, even in cases previously treated with platinum. Additionally, our findings indicate that CD5 positivity could be associated with improved PFS, suggesting its potential as a prognostic marker.Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Thymoma
/
Thymus Neoplasms
/
Antineoplastic Agents
Limits:
Humans
Language:
En
Journal:
Thorac Cancer
Year:
2024
Document type:
Article
Affiliation country: